Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Roche Holding Confirms 2023 Guidance Amidst Challenging Sales Environment


Roche Holding, the Swiss pharmaceutical giant, has reaffirmed its guidance for 2023 despite a decline in sales during the first nine months of the year. While the pharmaceutical division saw modest growth, this was overshadowed by a significant drop in diagnostics sales due to weaker demand caused by the ongoing Covid-19 pandemic.

According to Roche’s latest report, sales for the first nine months totaled 44.05 billion Swiss francs ($49 billion), representing a 6% decrease compared to the previous year. The pharma division experienced a 1% increase in sales, while diagnostics sales plummeted by 25%.

However, when accounting for currency fluctuations, the company reported a 1% sales growth for the year-to-date period and a 7% increase in the third quarter alone.

Looking ahead, Roche anticipates a low single-digit decline in group sales for 2023 at constant-exchange rates. Moreover, core earnings per share are expected to align with the projected sales drop, both at constant-exchange rates.

Despite the challenging market conditions, Roche remains confident in its long-term strategy and is committed to delivering sustainable growth. The company’s steadfast position on its 2023 guidance demonstrates its resilience and determination to navigate through these turbulent times.

PPG Industries Reports Strong Third-Quarter Results

Previous article

Tesla Stock Drops in Wake of Earnings, Analysts Find Silver Linings

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News